2020 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline report presents a comprehensive overview of the research and development of Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Three drugs in Pre-clinical phase and five drugs in Phase 1
As of February 2020, the Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline remains robust with 8 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) treatment. Diverse types of targeted therapies are being explored through clinical trials including Cannabinoid receptor agonist; Cholesterol 24-hydroxylase inhibitor; enzyme farnesyl pyrophosphate synthase; NMDA receptor antagonist; Neuromuscular blocking agents; Opioid receptor agonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) pipeline drugs profiled in the report include- BHV-5000, onabotulinumtoxinA, ketamine, T-121, NTRX-07, hydromorphone intrathecal, soticlestat (TAK-935), PPP001
As of February 2020, the Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline remains robust with 8 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) treatment. Diverse types of targeted therapies are being explored through clinical trials including Cannabinoid receptor agonist; Cholesterol 24-hydroxylase inhibitor; enzyme farnesyl pyrophosphate synthase; NMDA receptor antagonist; Neuromuscular blocking agents; Opioid receptor agonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) development
- Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline candidates included
- Business overview and snapshot of all companies involved in Complex Regional Pain Syndrome (Reflex Sympathetic Dystrophy) pipeline are included
- Latest market and pipeline developments are provided in the report
Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) pipeline drugs profiled in the report include- BHV-5000, onabotulinumtoxinA, ketamine, T-121, NTRX-07, hydromorphone intrathecal, soticlestat (TAK-935), PPP001
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) Condition
2.3 Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) Pipeline Snapshot, 2020
2.4 Companies investing in Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) pipeline therapeutics
2.5 Phase wise Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) Pipeline Products
2.7 Route of Administration of Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Allergan Plc Overview, Contacts and ASD Pipeline Drugs
3.2 Bexson Biomedical Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Biohaven Pharmaceutical Holding Company Ltd Overview, Contacts and ASD Pipeline Drugs
3.4 NeuroTherpia Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Piramal Enterprises Ltd Overview, Contacts and ASD Pipeline Drugs
3.6 Takeda Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.7 Tetra Bio-Pharma Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Thar Pharmaceuticals Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 BHV-5000 Drug Details
4.1.1 BHV-5000 Current Status
4.1.2 BHV-5000 Drug Overview
4.1.3 BHV-5000 Mechanism of Action
4.1.4 BHV-5000 Licensing/Collaboration Companies
4.1.5 BHV-5000 Clinical Trials
4.2 onabotulinumtoxinA Drug Details
4.2.1 onabotulinumtoxinA Current Status
4.2.2 onabotulinumtoxinA Drug Overview
4.2.3 onabotulinumtoxinA Mechanism of Action
4.2.4 onabotulinumtoxinA Licensing/Collaboration Companies
4.2.5 onabotulinumtoxinA Clinical Trials
4.3 ketamine Drug Details
4.3.1 ketamine Current Status
4.3.2 ketamine Drug Overview
4.3.3 ketamine Mechanism of Action
4.3.4 ketamine Licensing/Collaboration Companies
4.3.5 ketamine Clinical Trials
4.4 T-121 Drug Details
4.4.1 T-121 Current Status
4.4.2 T-121 Drug Overview
4.4.3 T-121 Mechanism of Action
4.4.4 T-121 Licensing/Collaboration Companies
4.4.5 T-121 Clinical Trials
4.5 NTRX-07 Drug Details
4.5.1 NTRX-07 Current Status
4.5.2 NTRX-07 Drug Overview
4.5.3 NTRX-07 Mechanism of Action
4.5.4 NTRX-07 Licensing/Collaboration Companies
4.5.5 NTRX-07 Clinical Trials
4.6 hydromorphone intrathecal Drug Details
4.6.1 hydromorphone intrathecal Current Status
4.6.2 hydromorphone intrathecal Drug Overview
4.6.3 hydromorphone intrathecal Mechanism of Action
4.6.4 hydromorphone intrathecal Licensing/Collaboration Companies
4.6.5 hydromorphone intrathecal Clinical Trials
4.7 soticlestat (TAK-935) Drug Details
4.7.1 soticlestat (TAK-935) Current Status
4.7.2 soticlestat (TAK-935) Drug Overview
4.7.3 soticlestat (TAK-935) Mechanism of Action
4.7.4 soticlestat (TAK-935) Licensing/Collaboration Companies
4.7.5 soticlestat (TAK-935) Clinical Trials
4.8 PPP001 Drug Details
4.8.1 PPP001 Current Status
4.8.2 PPP001 Drug Overview
4.8.3 PPP001 Mechanism of Action
4.8.4 PPP001 Licensing/Collaboration Companies
4.8.5 PPP001 Clinical Trials
5. LATEST COMPLEX REGIONAL PAIN SYNDROME (SYMPATHETIC REFLEX DYSTROPHY/REFLEX SYMPATHETIC DYSTROPHY) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) Condition
2.3 Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) Pipeline Snapshot, 2020
2.4 Companies investing in Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) pipeline therapeutics
2.5 Phase wise Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) Pipeline Products
2.7 Route of Administration of Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Allergan Plc Overview, Contacts and ASD Pipeline Drugs
3.2 Bexson Biomedical Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Biohaven Pharmaceutical Holding Company Ltd Overview, Contacts and ASD Pipeline Drugs
3.4 NeuroTherpia Inc Overview, Contacts and ASD Pipeline Drugs
3.5 Piramal Enterprises Ltd Overview, Contacts and ASD Pipeline Drugs
3.6 Takeda Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.7 Tetra Bio-Pharma Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Thar Pharmaceuticals Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 BHV-5000 Drug Details
4.1.1 BHV-5000 Current Status
4.1.2 BHV-5000 Drug Overview
4.1.3 BHV-5000 Mechanism of Action
4.1.4 BHV-5000 Licensing/Collaboration Companies
4.1.5 BHV-5000 Clinical Trials
4.2 onabotulinumtoxinA Drug Details
4.2.1 onabotulinumtoxinA Current Status
4.2.2 onabotulinumtoxinA Drug Overview
4.2.3 onabotulinumtoxinA Mechanism of Action
4.2.4 onabotulinumtoxinA Licensing/Collaboration Companies
4.2.5 onabotulinumtoxinA Clinical Trials
4.3 ketamine Drug Details
4.3.1 ketamine Current Status
4.3.2 ketamine Drug Overview
4.3.3 ketamine Mechanism of Action
4.3.4 ketamine Licensing/Collaboration Companies
4.3.5 ketamine Clinical Trials
4.4 T-121 Drug Details
4.4.1 T-121 Current Status
4.4.2 T-121 Drug Overview
4.4.3 T-121 Mechanism of Action
4.4.4 T-121 Licensing/Collaboration Companies
4.4.5 T-121 Clinical Trials
4.5 NTRX-07 Drug Details
4.5.1 NTRX-07 Current Status
4.5.2 NTRX-07 Drug Overview
4.5.3 NTRX-07 Mechanism of Action
4.5.4 NTRX-07 Licensing/Collaboration Companies
4.5.5 NTRX-07 Clinical Trials
4.6 hydromorphone intrathecal Drug Details
4.6.1 hydromorphone intrathecal Current Status
4.6.2 hydromorphone intrathecal Drug Overview
4.6.3 hydromorphone intrathecal Mechanism of Action
4.6.4 hydromorphone intrathecal Licensing/Collaboration Companies
4.6.5 hydromorphone intrathecal Clinical Trials
4.7 soticlestat (TAK-935) Drug Details
4.7.1 soticlestat (TAK-935) Current Status
4.7.2 soticlestat (TAK-935) Drug Overview
4.7.3 soticlestat (TAK-935) Mechanism of Action
4.7.4 soticlestat (TAK-935) Licensing/Collaboration Companies
4.7.5 soticlestat (TAK-935) Clinical Trials
4.8 PPP001 Drug Details
4.8.1 PPP001 Current Status
4.8.2 PPP001 Drug Overview
4.8.3 PPP001 Mechanism of Action
4.8.4 PPP001 Licensing/Collaboration Companies
4.8.5 PPP001 Clinical Trials
5. LATEST COMPLEX REGIONAL PAIN SYNDROME (SYMPATHETIC REFLEX DYSTROPHY/REFLEX SYMPATHETIC DYSTROPHY) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
